XML 114 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Debt Obligations - Additional Information (Detail)
€ in Millions, $ in Millions
1 Months Ended 12 Months Ended
Jul. 31, 2019
USD ($)
Dec. 31, 2019
EUR (€)
Dec. 31, 2019
USD ($)
Nov. 30, 2019
USD ($)
Nov. 15, 2019
USD ($)
Jun. 30, 2019
USD ($)
Apr. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Nov. 30, 2015
USD ($)
Debt Instrument [Line Items]                  
Revolving credit facility             $ 2,300   $ 3,000
Senior notes     $ 26,496         $ 28,483  
Debt instrument redeemed amount     $ 2,300            
Long term debt currency portion USD   66.00% 66.00%            
Long term debt currency portion EUR   31.00% 31.00%            
Long term debt currency portion CHF   3.00% 3.00%            
Netherlands II B.V. [Member]                  
Debt Instrument [Line Items]                  
Senior notes       $ 1,000          
Netherlands III B.V. [Member]                  
Debt Instrument [Line Items]                  
Senior notes       1,000          
Senior notes USD 1,700 million [Member]                  
Debt Instrument [Line Items]                  
Senior notes [1]               1,700  
Debt instrument face amount     $ 1,556            
Weighted average interest rate 1.70% 1.70% [1] 1.70% [1]            
Repayments of short-term debt $ 1,556                
Senior notes USD 1,700 million [Member] | Senior Notes [Member]                  
Debt Instrument [Line Items]                  
Senior notes           $ 1,700      
Debt instrument redeemed amount           $ 144      
Weighted average interest rate           1.70%      
Senior notes EUR 1,660 million [Member]                  
Debt Instrument [Line Items]                  
Senior notes [2]     $ 1,131         1,897  
Debt instrument redemption amount | €   € 650              
Debt instrument face amount | €   € 1,010              
Weighted average interest rate [2]   0.38% 0.38%            
Senior notes USD 3,000 million [Member]                  
Debt Instrument [Line Items]                  
Senior notes [3]     $ 1,474         2,997  
Debt instrument redemption amount       1,525          
Debt instrument face amount     $ 1,475 $ 3,000          
Weighted average interest rate   2.20% [3] 2.20% [3] 2.20%          
Senior notes USD 1,000 million [Member]                  
Debt Instrument [Line Items]                  
Senior notes [4]     $ 1,120            
Debt instrument face amount | €   € 1,000              
Weighted average interest rate   6.00% [4] 6.00% [4] 6.00%          
Senior notes USD 1,000 million [Member]                  
Debt Instrument [Line Items]                  
Senior notes [5]     $ 1,000            
Debt instrument face amount     $ 1,000            
Weighted average interest rate   7.13% [5] 7.13% [5] 7.125%          
Convertible Debt [Member]                  
Debt Instrument [Line Items]                  
Weighted average interest rate   0.25% 0.25%            
Principal amount currently outstanding on the debt instruments     $ 514         $ 514  
Revolving Credit Facility [Member]                  
Debt Instrument [Line Items]                  
Debt Instrument, Covenant Description   The net debt to EBITDA ratio limit was 6.25x through December 31, 2019, gradually declines to 5.75x in the third and fourth quarters of 2020, and continues to gradually decline over the remaining term of the RCF.              
Long Term Debt Payable Under Revolving Credit Facility         $ 0        
[1] During the first six months of 2019, Teva repurchased and canceled approximately $144 million principal amount of its $1,700 million 1.7% senior notes due in July 2019. In July 2019, Teva repaid at maturity $1,556 million of its 1.7% senior notes.
[2] In December 2019, Teva consummated an early redemption of 650 million Euro of its 1,660 million Euro 0.375% senior notes due in July 2020.
[3] In November 2019, Teva consummated a cash tender offer for its $3,000 million 2.2% senior notes due in July 2021. As a result of the offer, Teva redeemed $1,525 million aggregate principal amount of this senior note.
[4] In November 2019, Teva Pharmaceutical Finance Netherlands II B.V, a Teva finance subsidiary, issued senior notes in an aggregate principal amount of 1,000 million Euro.
[5] In November 2019, Teva Pharmaceutical Finance Netherlands III B.V, a Teva finance subsidiary, issued senior notes in an aggregate principal amount of $1,000 million.